The Multiple Sclerosis Treatment Optimization Program
Abstract Objective To design and implement a health system level intervention to reduce escalating multiple sclerosis (MS) disease modifying treatment (DMT) expenditures and improve outcomes. Methods We conducted stakeholder meetings, reviewed pharmacy utilization data, and abstracted information in...
Enregistré dans:
Auteurs principaux: | Annette Langer‐Gould, Stephen C. Cheng, Bonnie H. Li, Michael H. Kanter |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Wiley
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/b2d72556b04543fdaace7e951537f3da |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Review of teriflunomide and its potential in the treatment of multiple sclerosis
par: Clemens Warnke, et autres
Publié: (2009) -
Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
par: Warnke C, et autres
Publié: (2011) -
The role of glatiramer acetate in the early treatment of multiple sclerosis
par: David W Brandes
Publié: (2010) -
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
par: Lugaresi A, et autres
Publié: (2013) -
Measuring treatment response to advance precision medicine for multiple sclerosis
par: Peter A. Calabresi, et autres
Publié: (2021)